S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$228.74
$228.74
50-Day Range
$228.74
$228.74
52-Week Range
$123.77
$228.96
Volume
86 shs
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$229.00

Seagen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.1% Upside
$229.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.63
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.82) to ($1.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.24 out of 5 stars

Medical Sector

912th out of 938 stocks

Biotechnology Industry

26th out of 28 stocks

SGEN stock logo

About Seagen Stock (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

SGEN Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
How you can target big results without spending big money!
While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades!
MRNA Feb 2024 67.000 put
SGEN Jan 2024 210.000 put
SGEN Jan 2024 235.000 put(CONTR
SGEN Dec 2023 195.000 put(CONTR
HBM Gets Health Boost From Drug Licensing Deals
What the Options Market Tells Us About Seagen
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$229.00
High Stock Price Target
$229.00
Low Stock Price Target
$229.00
Potential Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-32.12%

Debt

Sales & Book Value

Annual Sales
$2.30 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
Optionable
Beta
0.32

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Should I Buy Seagen Stock? SGEN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Seagen was last updated on Monday, March 25, 2024 at 11:05 PM.

Pros

Here are some ways that investors could benefit from investing in Seagen Inc.:

  • Seagen Inc. has a strong product portfolio including ADCETRIS, PADCEV, and TUKYSA, which are innovative therapies for cancer treatment.
  • Recent acquisition of Seagen Inc. shares by Hudson Bay Capital Management LP indicates investor confidence in the company's potential growth.
  • Seagen Inc. has collaboration agreements with reputable companies like Takeda Pharmaceutical, Merck, and Genmab, enhancing its research and development capabilities.
  • Seagen Inc. is continuously developing new therapies like TIVDAK, Ladiratuzumab Vedotin, and Disitamab Vedotin, expanding its product pipeline.
  • Despite being a subsidiary of Pfizer Inc., Seagen Inc. operates independently, allowing it to focus on its core competencies in biotechnology.

Cons

Investors should be bearish about investing in Seagen Inc. for these reasons:

  • Market volatility in the biotechnology sector can impact Seagen Inc.'s stock price, leading to potential investment risks.
  • Regulatory challenges and approval processes for new drugs can cause delays in product launches, affecting revenue generation.
  • Competition in the biotechnology industry is intense, with other companies also developing innovative cancer therapies, posing a threat to Seagen Inc.'s market share.
  • Fluctuations in healthcare policies and reimbursement rates can influence the adoption of Seagen Inc.'s products, affecting financial performance.
  • Investing in biotechnology companies like Seagen Inc. requires a high tolerance for risk due to the inherent uncertainties in drug development and commercialization.

SGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for Seagen's stock. Their SGEN share price targets range from $229.00 to $229.00. On average, they anticipate the company's share price to reach $229.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.33. The biotechnology company had revenue of $648.65 million for the quarter, compared to analyst estimates of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. Seagen's revenue for the quarter was up 27.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.03) EPS.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Clear Street Markets LLC (0.00%), Public Sector Pension Investment Board (0.00%), Mint Tower Capital Management B.V. (0.00%), Neuberger Berman Group LLC (0.00%), Cowen AND Company LLC (0.00%) and Segantii Capital Management Ltd (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
This page (NASDAQ:SGEN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners